JPH08502722A - Il−6含有薬剤組成物 - Google Patents
Il−6含有薬剤組成物Info
- Publication number
- JPH08502722A JPH08502722A JP5519841A JP51984193A JPH08502722A JP H08502722 A JPH08502722 A JP H08502722A JP 5519841 A JP5519841 A JP 5519841A JP 51984193 A JP51984193 A JP 51984193A JP H08502722 A JPH08502722 A JP H08502722A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sucrose
- solution
- composition according
- trehalose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 30
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 39
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 229930006000 Sucrose Natural products 0.000 claims abstract description 24
- 239000005720 sucrose Substances 0.000 claims abstract description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 19
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 17
- 235000000346 sugar Nutrition 0.000 claims abstract description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 13
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 13
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 13
- 150000008163 sugars Chemical class 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 19
- 239000008247 solid mixture Substances 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- 125000000185 sucrose group Chemical group 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 26
- 102000008100 Human Serum Albumin Human genes 0.000 abstract description 6
- 108091006905 Human Serum Albumin Proteins 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010874 maintenance of protein location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.インターロイキン-6(IL-6)および非還元糖単独または他の賦形剤と合わ せた非還元糖のいずれかの安定化量からなる均質固体混合物を含む薬剤組成物。 2.前記均質固体混合物がフリーズドライした粉末である請求項1の薬剤組成物 。 3.前記非還元糖がショ糖またはトレハロースである請求項1および2の薬剤組 成物。 4.前記IL-6が組換え体である請求項1-3のいずれか1項の薬剤組成物。 5.前記安定剤がショ糖またはトレハロース単独である請求項1-4のいずれか 1項の薬剤組成物。 6.前記安定剤がアミノ酸と一緒のショ糖またはトレハロースである請求項1- 4のいずれか1項の薬剤組成物。 7.前記アミノ酸がアルギニンである請求項6の薬剤組成物。 8.前記安定剤がアルブミンと−緒のショ糖またはトレハロースである請求項1 -4のいずれか1項の薬剤組成物。 9.IL-6 35または350μgおよびショ糖48mgを含む請求項1-8のいずれか1項の 薬剤組成物。 10.IL-6 35または350μgおよびトレハロース47.5mgを含む請求項1-8のいずれ か1項の薬剤組成物。 11.以下の工程:成分水溶液を調製し、これを容器へ分散させ、そして容器中で これを乾燥またはフリーズドライすることからなる請求項1-10のいずれか1 項の薬剤組成物の調製方法。 12.以下の工程:成分水溶液を調製し、これを乾燥またはフリーズドライし、そ して得られた固体混合物を容器へ分散させることからなる請求項1-10のいず れか1項の薬剤組成物の調製方法。 13.溶液渾が4.5〜8.5の範囲である請求項11および12の方法。 14.溶液pHが7である請求項13の方法。 15.使用前の貯蔵に適しそして注射用の溶媒または溶液中で混合物を再構成する のに適する滅菌容器に密閉された請求項1-10のいずれか1項の均質固体混合 物を含む薬剤組成物の形態。 16.注射用の溶媒または溶液中で再構成された請求項15の固体混合物含有溶液。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT92A000349 | 1992-04-17 | ||
ITRM920349A IT1254359B (it) | 1992-05-11 | 1992-05-11 | Composizioni farmaceutiche contenenti il-6 |
PCT/EP1993/001120 WO1993023065A1 (en) | 1992-05-11 | 1993-05-07 | Pharmaceutical compositions containing il-6 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08502722A true JPH08502722A (ja) | 1996-03-26 |
JP3714951B2 JP3714951B2 (ja) | 2005-11-09 |
Family
ID=11400994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51984193A Expired - Fee Related JP3714951B2 (ja) | 1992-05-11 | 1993-05-07 | Il−6含有薬剤組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5635176A (ja) |
EP (1) | EP0641216B1 (ja) |
JP (1) | JP3714951B2 (ja) |
AT (1) | ATE157256T1 (ja) |
AU (1) | AU676833B2 (ja) |
CA (1) | CA2117761C (ja) |
DE (1) | DE69313444T2 (ja) |
DK (1) | DK0641216T3 (ja) |
ES (1) | ES2105257T3 (ja) |
GR (1) | GR3024708T3 (ja) |
IT (1) | IT1254359B (ja) |
WO (1) | WO1993023065A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0820299B1 (en) * | 1995-02-06 | 2002-04-24 | Genetics Institute, Inc. | Formulations for il-12 |
GB9508691D0 (en) * | 1995-04-28 | 1995-06-14 | Pafra Ltd | Stable compositions |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
DE19539574A1 (de) | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren |
US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
US6632648B1 (en) * | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
US7141393B2 (en) * | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6433760B1 (en) | 1999-01-14 | 2002-08-13 | University Of Central Florida | Head mounted display with eyetracking capability |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
EP1356809A4 (en) * | 2000-12-28 | 2008-05-14 | Takeda Pharmaceutical | SUSTAINED RELEASE PREPARATIONS |
US7368102B2 (en) | 2001-12-19 | 2008-05-06 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
US20050118163A1 (en) * | 2002-02-14 | 2005-06-02 | Hidefumi Mizushima | Antibody-containing solution pharmaceuticals |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
DE229810T1 (de) * | 1985-07-09 | 1987-11-05 | Quadrant Bioresources Ltd., Soulbury, Leighton Buzzard, Bedfordshire | Beschuetzung von proteinen und aehnlichem. |
DE220574T1 (de) * | 1985-10-14 | 1987-11-26 | Yeda Research And Development Co., Ltd., Rehovot | Menschliches interferon-beta2a und interferon-beta2b |
US4762857A (en) * | 1986-05-30 | 1988-08-09 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
DE3621828A1 (de) * | 1986-06-28 | 1988-01-14 | Biotest Pharma Gmbh | Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff |
US5078997A (en) * | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
US5104651A (en) * | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
JP2805224B2 (ja) * | 1989-01-13 | 1998-09-30 | 味の素株式会社 | 血小板減少症治療剤 |
JPH0327320A (ja) * | 1989-06-26 | 1991-02-05 | Ajinomoto Co Inc | ヒトb細胞分化因子医薬組成物 |
JPH05963A (ja) * | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
US5416071A (en) * | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
EP0560998A4 (en) * | 1991-10-09 | 1993-12-01 | Toray Industries, Inc. | Medicine for preventing and treating bleeding tendency |
JP3027320U (ja) | 1996-01-27 | 1996-08-09 | 三千男 高橋 | 野球グラブの装着補強具 |
-
1992
- 1992-05-11 IT ITRM920349A patent/IT1254359B/it active
-
1993
- 1993-05-07 DK DK93909917.2T patent/DK0641216T3/da active
- 1993-05-07 JP JP51984193A patent/JP3714951B2/ja not_active Expired - Fee Related
- 1993-05-07 CA CA002117761A patent/CA2117761C/en not_active Expired - Fee Related
- 1993-05-07 EP EP93909917A patent/EP0641216B1/en not_active Expired - Lifetime
- 1993-05-07 AT AT93909917T patent/ATE157256T1/de not_active IP Right Cessation
- 1993-05-07 WO PCT/EP1993/001120 patent/WO1993023065A1/en active IP Right Grant
- 1993-05-07 ES ES93909917T patent/ES2105257T3/es not_active Expired - Lifetime
- 1993-05-07 AU AU40653/93A patent/AU676833B2/en not_active Ceased
- 1993-05-07 US US08/335,874 patent/US5635176A/en not_active Expired - Fee Related
- 1993-05-07 DE DE69313444T patent/DE69313444T2/de not_active Expired - Fee Related
-
1997
- 1997-09-11 GR GR970402352T patent/GR3024708T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU676833B2 (en) | 1997-03-27 |
ITRM920349A0 (it) | 1992-05-11 |
US5635176A (en) | 1997-06-03 |
IT1254359B (it) | 1995-09-14 |
CA2117761C (en) | 2005-10-04 |
GR3024708T3 (en) | 1997-12-31 |
DE69313444T2 (de) | 1998-01-02 |
EP0641216B1 (en) | 1997-08-27 |
JP3714951B2 (ja) | 2005-11-09 |
DK0641216T3 (da) | 1998-01-26 |
DE69313444D1 (de) | 1997-10-02 |
WO1993023065A1 (en) | 1993-11-25 |
CA2117761A1 (en) | 1993-11-25 |
ATE157256T1 (de) | 1997-09-15 |
ITRM920349A1 (it) | 1993-11-11 |
AU4065393A (en) | 1993-12-13 |
EP0641216A1 (en) | 1995-03-08 |
ES2105257T3 (es) | 1997-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4496537A (en) | Biologically stable alpha-interferon formulations | |
EP0409870B1 (en) | Human growth hormone formulation | |
HU225494B1 (en) | Stable, aqueous alfa interferon solution formulations | |
JPH08502722A (ja) | Il−6含有薬剤組成物 | |
JP3702313B2 (ja) | ゴナドトロピン含有薬剤組成物 | |
KR20080106636A (ko) | 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액 | |
JP3701675B2 (ja) | IFN−β液体製剤 | |
EP1641486B1 (en) | Stable, aqueous solution of human erythropoietin, not containing serum albumin | |
JPH0314520A (ja) | インターロイキン―1組成物 | |
SK862004A3 (en) | Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan | |
WO1993005799A1 (en) | Lyophilized stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor | |
KR100567358B1 (ko) | 0.5밀리리터 미만의 부피를 투여하기 위한, 동결건조된단백질 조성물을 포함하는 일회 투여용 주사기 | |
CN115364060A (zh) | 一种冻干药物制剂及其用途 | |
KR880002037B1 (ko) | 인터페론 조성물 및 이의 제조방법 | |
WO2019220654A1 (ja) | N-ホルミルピぺリジン含有量が低減されている、及び/又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤 | |
US5340574A (en) | Stabilized non-glycosylated recombinant human IL2 in reduced form compositions | |
JP6445169B2 (ja) | α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤 | |
CA2374933C (en) | Grf-containing lyophilized pharmaceutical compositions | |
US5169834A (en) | Compositions and method for reducing vial breakage during lyophilization | |
RU2236866C2 (ru) | Препарат на основе рекомбинантного альфа-2 интерферона человека для инъекций в сухой лиофилизированной форме | |
CN116685309A (zh) | 改善的冻干制剂 | |
AU2005200879B2 (en) | GRF-containing lyophilized pharmaceutical compositions | |
JPS62149623A (ja) | 安定なgrf製剤 | |
MXPA03008545A (es) | Composiciones farmaceuticas que contienen la hormona humana del crecimiento. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20031215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040129 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050601 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050809 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050824 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |